Afleveringen
-
Virtual wards (also known as hospital at home) allow patients to get the care they need at home safely and conveniently, rather than being in hospital. The NHS is increasingly introducing virtual wards to support people at the place they call home, including care homes.
In today’s podcast, web editor Nicole Raleigh speaks with Dr Samuel Ewing, global head of pharma partnerships at Doccla, about the next generation of digital tools such as wearable medical devices, as well as remote patient monitoring and digital healthcare generally.
Although wearables go back decades, the true benefit for patients and healthcare systems allows home monitoring. Explaining a current COPD example, it’s about reducing hospital admissions, says Ewing, thereby reducing burden, and its also about more individualised care, on which point Ewing explores the current physician grading scale of Parkinson’s symptoms compared to remote and daily patient monitoring.
In short, technology is transforming healthcare today, but there’s still a lot of work to do. Yet, Ewing caveats against ‘hysteria’ around data management and posits that there is perhaps too much concern over data privacy.
-
Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high.
In today’s podcast, web editor Nicole Raleigh speaks with Dr Neal Kassell, chair and founder of the Focused Ultrasound Foundation and previously a neurosurgeon, who created the Foundation in 2006 to improve the lives of millions of people with serious medical disorders by accelerating the development and adoption of focused ultrasound.
Focus ultrasound (FUS) has the potential to revolutionise therapy to the same degree that magnetic resonance imaging (MRI) scanning revolutionised diagnosis, says Kassell. The effect of the treatment can be observed as it is being administered in real time by using such imaging; it is image-guided therapy.
Of the 180 indications in various stages of development using FUS, the number of regulatory approvals and reimbursements is increasing. Dialogue has shifted from ‘if’ to ‘when’ and the Focused Ultrasound Foundation works to make that when ‘now’. And it all begins with evidence, evidence come from research.
-
Zijn er afleveringen die ontbreken?
-
A digital health passport is an app, or online certification, that displays a traveller’s health or vaccination record. It can save lives, on both private and public levels.
In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Matt Hollingsworth, co-founder and CEO of Carta Healthcare, a company seeking to support the healthcare data registry market by transforming a previously manual clinical data abstraction process.
Hollingsworth discusses his own, very personal experiences that led to Carta Healthcare’s foundation and progressed its work, as well as the comfort that can be provided patients with chronic diseases – including congenital heart defects – with digital health passports, offering an information safety net for them whilst travelling, circumventing the need to carry veritable folders full of printed health records.
Diving into the what’s what of EHRs, AI’s role in digital health passports, and the pros and cons of a generally digital future, technology is nevertheless very much in our health futures, explains Hollingsworth.
-
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens. The technology proved vital in aiding understanding of the evolution of and spread of virus in real time to inform public health measures, ultimately accelerating drug and vaccine development.
In today’s podcast, web editor Nicole Raleigh speaks with Dr Evan Floden, CEO and co-founder of Seqera, a data orchestration and genomics analysis company, about barriers of entry to genomic surveillance in public health labs and how these can be lowered to support future bioinformaticians, aiding acceleration and quality and accuracy in R&D.
-
Precision medicine is oft spoken about these days, as it is finally addressing the elephant in the room: one size – or, more appropriately, one dose – does not fit all. Precision medicine hones in on treatment of the individual, rather than just the disease, focusing on the reality that each patient is biologically different. Personalisation is very much key.
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Hakim Yadi, PhD, OBE, and CEO and co-founder of Closed Loop Medicine, ahead of his appearance at Frontiers Health next week, 17th-18th October.
Closed Loop Medicine is a TechBio company developing prescription combination drug plus software products, with the aim of bring forward the promise of precision medicine. From personalised dosing to the applicability of this approach to the GLP-1 trend in obesity treatment, the conversation covers recent collaborations and harks back to discussions at the Galien Forum earlier in 2024, honing in on the importance of workflow and cost considerations, also.
-
Investment and strategic partnerships are the lifeblood of innovation in healthcare, driving groundbreaking discoveries and accelerating the development of life-changing therapies. And so, it was no surprise that the 2024 LSX USA Congress in Boston attracted life sciences innovators and decision-makers from around the world, eager to explore the latest trends shaping the industry.
Among those attendees was pharmaphorum’s editor-in-chief, Jonah Comstock, who took to the floor to uncover the trends and talking points set to influence investment decisions in the coming months.
In this special episode of the pharmaphorum podcast, Jonah sat down with Deep Dive editor Eloise McLennan to discuss key takeaways from the LSX conference. From evolving investment trends like AI in biotech and digital to emerging areas such as precision psychiatry, they explore the cautiously optimistic investment landscape, the delicate balance between early- and late-stage investments, and the importance of building honest, productive relationships across the healthcare ecosystem.
Tune in to hear their in-depth analysis of the latest investment and partnership trends shaping the future of healthcare innovation.
-
The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest data, communicating the next promising steps in oncological scientific development, ever seeking to address unmet patient needs.
So it was that pharmaphorum Web Editor Nicole Raleigh found a quiet spot onsite in Barcelona this year to catch with experts from EVERSANA and discuss their takeaways from the 2024 conference. Tune in to hear more from: Ann Marie Robertson, Chief Commercial Officer, EVP, EVERSANA COMPLETE Oncology, EVERSANA; Barry Vucsko, Senior Vice President, Client Services and Business Development Leader, EVERSANA INTOUCH; Vanitha Sankaran, VP, Medical Strategy, EVERSANA INTOUCH; and Gurdip Daffu, PhD, VP, Medical Strategy (Oncology), EVERSANA INTOUCH.
From the unique to the specifics of antibody-drug conjugates (ADCs) and advancements in women’s cancers, to the proliferation of AI and where it’s all going, and from diagnostics to excitement and hope at what’s on the cusp and what’s yet to come – the sense of bated breath potential is palpable.
-
Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the drug negotiation provisions in the Inflation Reduction Act. The industry has been waiting with bated breath to see these prices, as they give the first real indication of how impactful this unprecedented legislation will be for pharma’s bottom line.
But this latest release of information raises as many questions as it answers, and on today’s podcast host Jonah Comstock is joined by Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert, for a broad ranging discussion of some of the next steps and consequences – intended or otherwise – of this legislation.
They talk about the many challenges CMS is likely to face in operationalising these prices and how much of the savings is likely to find its way to patients when the dust settles. They also discuss the prices themselves, why they aren’t lower, and just how low they really are, contextually. Additionally, they discuss some of the downstream consequences still to come from the IRA, including possible effects on oncolytics and the generics market.
For the pharma industry, the IRA drug pricing negotiation provision is shaping up to be one of the most consequential political stories of the decade. Tune in for a lively and in-depth discussion of what those consequences might look like.
-
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpointing and showcasing repeatable use cases to shape the targeted use of next-generation artificial intelligence and machine learning (AI-ML) innovation, particularly in the form of GenAI.
In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Manny Belabe, senior VP of customer success at ArisGlobal, about the Council and the role it seeks to play in furthering the success of GenAI in life sciences R&D.
Discussing also ArisGlobal’s LifeSphere NavaX GenAI features and functionality, Belabe notes too that a platform-centric development approach, based on common modules, can be leveraged to reduce data redundancy and general maintenance of that data.
At the present moment, however, there is also the pressing concern of sustainability in all sectors, and Belabe addresses practical issues around cooling infrastructure and space requirements for these technologies, as well.
-
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Fiske, chief scientific officer of Mythic Therapeutics, about minimising side effects for patients and the notion of patient-centred science.
-
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jane Reed, director of life sciences at Linguamatics, an IQVIA company, to discuss some of the major barriers preventing researchers from accessing the data they need to advance drug discovery and development and address safety concerns – and just how AI technologies can assist.
-
With the implementation of advancing technologies in industry comes the parallel need for suitable upskilling of the workforce – but this doesn’t as yet always pan out, and in today’s pharmaphorum podcast COO of Enthought Mike Connell discusses the growing skills gap in R&D in life sciences and the 80/20 rule with web editor Nicole Raleigh, as well as the need for correct education of people and machines, both.
-
Chronic cough impacts up to 10% of the adult population and has a physical, psychological, and social impact on patients’ lives.
Farrell Simon, chief commercial officer at Trevi Therapeutics, joins web editor Nicole Raleigh on the pharmaphorum podcast to discuss prioritising patients in clinical and commercial development, with an especial focus on chronic cough.
There are currently no approved therapies in either the US or the UK for what is a highly disruptive affliction, accompanied by a wide range of complications, which causes a significant burden on patients, caregivers, and healthcare systems.
Also discussing Trevi’s own work in the field, in particular a potential treatment for idiopathic pulmonary fibrosis (IPF), the conversation explores how to work more closely and holistically with patients in clinical development. Integrating the patient voice is, as Simon says, critical in clinical trial design. After all, the patient is the utmost stakeholder.
-
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ethan Drower, co-founder and CEO of Cite Medical Solutions, a company providing full Clinical Evaluation Report (CER) services and industry literature review for European Union Medical Device Regulation (or EU MDR) processes.
-
One of the things that makes patient engagement for pharma companies so challenging is that it's not something that can be added to one step of a process and then checked off the list. Real patient engagement needs to be integrated into processes every step of the way.
In today's podcast, brought to you by Reverba, Reverba CEO Cheryl Lubbert joins host Jonah Comstock to walk through the steps of the product lifestyle and explore the role of the patient at each of those stages: from preclinical through commercialisation and beyond.
Lubbert discusses the relationship between patient engagement, patient activation, patient centricity, and patient co-creation. She gives a wealth of examples from her experience as a long-time leader in the pharma industry to give context to the many ways to incorporate patients and their feedback into product discovery, clinical trials, product development, launch, and post-launch.
Finally, at the end of the podcast Lubbert gets into a few other hot-button issues including diversity and representation, as well as AI and how it will affect patient engagement. Tune in for interesting and actionable tips about patient engagement in pharma.
-
In today’s podcast, web editor Nicole Raleigh speaks with Carolyn Ward, director of clinical strategy at Particle Health Inc, a data transformation platform for healthcare, enabling organisations across the care continuum to turn medical records into actionable insights.
-
In today’s podcast, web editor Nicole Raleigh welcomes Dr Catherine Beech, CEO of Exonate, for a discussion on retinal vascular disease and a potential eye drop treatment for diabetic retinopathy and diabetic macular oedema, instead of invasive injections into the eye.
-
When it comes to life sciences manufacturing, there's nothing quite so daunting as a tech transfer - moving a product from development to commercialisation, or to a new facility or CDMO, presents many obstacles that have to be well thought out and planned. Delivering a tech transfer on schedule that stays below budget is no easy feat, but with the right best practices it can be done.
In today's podcast, brought to you by Lannett CDMO, Grant Brock, VP of operations at Lannett CDMO, and Frantz Maignan, Lannett CDMO's director of validation and tech services, join host Jonah Comstock for a deep dive into what challenges companies can encounter when it comes to tech transfers and some standout strategies for avoiding and surmounting those challenges.
The discussion includes the importance of thorough preparation and experimentation, good communication, and flexibility, and Brock and Maignan offer a few tips for choosing a manufacturing partner that can handle the unexpected bumps in the road that can crop up.
Tune in for a practical guide to an important and oft-overlooked aspect of pharma manufacturing.
-
We've recently passed the midpoint of 2024, so it's a good time to check in on trends – in this case, trends in the clinical trial space.
In today's podcast, brought to you by Advanced Clinical, host Jonah Comstock is joined by Jason Casarella, EVP of business development and marketing at Advanced Clinical and Caroline Redecker, chief strategy officer at Advanced Clinical, to discuss some of the findings in their recently released clinical trends report.
One of the biggest trends in the report is the rise of clinical trial site networks, and Casarella and Redecker drill down on why that’s happening and what it means for investigators. They also discuss how patient recruitment is changing in light of both changing technology and infrastructures, and new expectations about representation and diversity.
The conversation also veers into biotech investment trends and how those impact clinical trials, as well as the rise of AI and the various use cases being found for it in clinical research. Tune in for a wide-ranging snapshot into the evolving world of clinical research.
-
In this latest pharmaphorum podcast, web editor Nicole Raleigh speaks with Michael Kyle, chief medical officer at Currax Pharmaceuticals – a company working to advance a greater understanding of how to effectively treat obesity – about perceptions and options beyond the bounds of GLP-1s, including evolution of hypertension treatments.
- Laat meer zien
